Why did shares in Hikma Pharmaceuticals plc and GlaxoSmithKline plc crash last week?

Shares in GlaxoSmithKline plc (LON: GSK) and Hikma Pharmaceuticals plc (LON: HIK) are crashing but should you sell?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the beginning of October, shares in GlaxoSmithKline(LSE: GSK) and Hikma (LSE: HIK) have been on the retreat. After a rally during the first six months of the year (shares in Glaxo and Hikma rose 20% and 15% respectively in H1), since the beginning of October Glaxo has lost approximately 7% and Hikma is down 20%. 

This sell-off accelerated last week. Over the past seven days, shares in Hikma have lost 6% and Glaxo’s shares are down by 4%, both exceeding the FTSE 100’s decline of 2.3% over the same period. 

The big question is, what’s the reason for these declines and will they continue? 

Pharma falling out of favour 

One of the developments that could be to blame for the recent declines is the buzz around the US election. Healthcare reform has been a key debating point among all candidates since the beginning of campaigning. There’s a fear among investors, especially over in the US, that the incoming president could force companies to lower their drug prices, decimating profitability. These concerns have sent the shares in major US pharmaceutical companies plunging. During the past two months, the SPDR S&P Pharmaceuticals ETF has dropped by 18%. 

Alongside election concerns, shares in Glaxo and Hikma have come under pressure from a stronger pound. When the value of sterling plunged, their shares jumped as weak sterling means higher profits. But a stronger sterling will erase some FX-induced profit boost, and with profits set to come in lower than expected, it makes perfect sense that the shares would fall. Since the beginning of November, sterling has strengthened by around 3%-4%. 

Still attractive 

Glaxo and Hikma may have fallen out of favour with investors during the past few weeks, but these companies remain attractive long-term investments. 

City analysts expect Hikma’s earnings per share to fall by 24% this year due to one-off effects, before rebounding by 35% during 2017 as the company’s revenue and profitability hits an all-time high. Based on 2017 forecasts, shares in the company are currently trading at a forward P/E of 13.8, which looks cheap for a fast-growing defensive company like Hikma.

City analysts expect Glaxo’s earnings per share to jump by 31% this year and a further 9% during 2017 as the company benefits from a weaker sterling and organic growth. What’s more, management has stated that the firm’s 80p share dividend payout is here to stay for the foreseeable future, so that market-leading yield of 5.2% isn’t at risk in the near term.

The bottom line 

So overall, it would appear that shares in Glaxo and Hikma dropped last week due to outlook concerns. However, for the time being, the outlook for these companies remains bright and after recent declines, the shares trade at extremely attractive valuations. For the long-term investor then, now might be the time to buy Glaxo and Hikma on weakness. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »